Literature DB >> 12540499

Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression.

Yue Xu1, Atsuko Shibata, John E McNeal, Thomas A Stamey, David Feldman, Donna M Peehl.   

Abstract

Vitamin D plays an important role in cell growth and differentiation and is proposed to protect against cancer initiation and/or progression. The vitamin D receptor (VDR) has a thymine/cytosine (T/C) polymorphism located in the first of two potential start (ATG) codons that can be detected by a RFLP using the endonuclease FokI. The C variant, which lacks the first ATG, results in a shorter VDR and is referred to as the F allele. The T variant (f allele) initiates at the first ATG. We examined the association of the VDR FokI genotype with histopathological characteristics and prognosis of prostate cancer among 191 mostly Caucasian subjects who had undergone radical prostatectomy between 1984 and 1992. The frequencies of the FF, Ff, and ff genotypes were 41%, 38%, and 21%, respectively. Subjects with the ff genotype had a lower mean percentage of Gleason grade 4/5 cancer (30.3%) than subjects with the FF or Ff genotypes (42.8% and 43.8%, respectively; P = 0.015 by t test for ff versus FF + Ff). The data suggest that the presence of an F allele increased the risk of being diagnosed with more aggressive cancer because higher percentage of Gleason grade 4/5 is associated with worse prognosis. The age-adjusted risk of prostate-specific antigen failure was lower for the ff genotype than for the FF genotype by Cox proportional hazards analysis but did not achieve statistical significance (hazard ratio = 0.76; 95% confidence interval, 0.44-1.32). This risk reduction disappeared after further adjustment for percentage of Gleason grade 4/5, cancer volume, and preoperative serum prostate-specific antigen level (hazard ratio = 1.03; 95% confidence interval, 0.58-1.85). In conclusion, the ff genotype was associated with less aggressive histopathological findings than Ff or FF genotypes. Additional studies with a larger sample size and investigation of the functional significance of the FokI polymorphism in prostate cancer cells are warranted.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12540499

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  15 in total

Review 1.  Prognostic role of vitamin d status and efficacy of vitamin D supplementation in cancer patients: a systematic review.

Authors:  Consuelo Buttigliero; Chiara Monagheddu; Paola Petroni; Andrea Saini; Luigi Dogliotti; Giovannino Ciccone; Alfredo Berruti
Journal:  Oncologist       Date:  2011-08-11

2.  Vitamin D receptor genetic polymorphisms are associated with PSA level, Gleason score and prostate cancer risk in African-American men.

Authors:  Emmanuel Y Jingwi; Muneer Abbas; Luisel Ricks-Santi; Danyelle Winchester; Desta Beyene; Agnes Day; Tammey J Naab; Olakunle O Kassim; Georgia M Dunston; Robert L Copeland; Yasmine M Kanaan
Journal:  Anticancer Res       Date:  2015-03       Impact factor: 2.480

3.  Vitamin D pathway gene variants and prostate cancer prognosis.

Authors:  Sarah K Holt; Erika M Kwon; Joseph S Koopmeiners; Daniel W Lin; Ziding Feng; Elaine A Ostrander; Ulrike Peters; Janet L Stanford
Journal:  Prostate       Date:  2010-09-15       Impact factor: 4.104

4.  Vitamin D receptor gene Tru9I polymorphism and risk for incidental sporadic colorectal adenomas.

Authors:  You-Ling Gong; Da-Wen Xie; Zong-Lin Deng; Roberd M Bostick; Xi-Jiang Miao; Jin-Hui Zhang; Zhi-Hong Gong
Journal:  World J Gastroenterol       Date:  2005-08-21       Impact factor: 5.742

5.  Thyroid cancer resistance to vitamin D receptor activation is associated with 24-hydroxylase levels but not the ff FokI polymorphism.

Authors:  Vibha Sharma; Deborah Fretwell; Zachary Crees; Anna Kerege; Joshua P Klopper
Journal:  Thyroid       Date:  2010-10       Impact factor: 6.568

6.  The elevated expression of a mismatch repair protein is a predictor for biochemical recurrence after radical prostatectomy.

Authors:  Alixanna M Norris; Michael Gentry; Donna M Peehl; Ralph D'Agostino; Karin D Scarpinato
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

Review 7.  Vitamin D receptor gene (VDR) associations with cancer.

Authors:  Martha L Slattery
Journal:  Nutr Rev       Date:  2007-08       Impact factor: 7.110

Review 8.  The role of vitamin D in reducing cancer risk and progression.

Authors:  David Feldman; Aruna V Krishnan; Srilatha Swami; Edward Giovannucci; Brian J Feldman
Journal:  Nat Rev Cancer       Date:  2014-04-04       Impact factor: 60.716

9.  Vitamin d: are we ready to supplement for breast cancer prevention and treatment?

Authors:  Katherine D Crew
Journal:  ISRN Oncol       Date:  2013-02-26

10.  Vitamin D receptor gene polymorphisms and prognosis of breast cancer among African-American and Hispanic women.

Authors:  Dhruva K Mishra; Yanyuan Wu; Marianna Sarkissyan; Suren Sarkissyan; Zujian Chen; Xiying Shang; May Ong; David Heber; H Phillip Koeffler; Jaydutt V Vadgama
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.